HASSAN RAHHAL

Índice h a partir de 2011
7
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 27
  • bookPart
    Ascite
    (2022) BRANDãO NETO, Rodrigo Antonio; RAHHAL, Hassan; VALENTE, Fernando Salvetti
  • bookPart
    Princípios básicos da oferta de oxigênio
    (2023) PEREIRA, Guilherme de Abreu; RAHHAL, Hassan; VALENTE, Fernando Salvetti
  • bookPart
    Síncope
    (2020) BRANDãO NETO, Rodrigo Antonio; MARCHINI, Júlio Flávio Meirelles; VALENTE, Fernando Salvetti; RAHHAL, Hassan
  • bookPart
    Derrame pleural
    (2020) PINTO, Patrick Aureo Lacerda de Almeida; BRANDãO NETO, Rodrigo Antonio; SOUZA, Heraldo Possolo de; RIBEIRO, Sabrina Côrrea da Costa; RAHHAL, Hassan; VALENTE, Fernando Salvetti
  • bookPart
    Síncope
    (2021) BRANDãO NETO, Rodrigo Antonio; MARCHINI, Júlio Flávio Meirelles; VALENTE, Fernando Salvetti; RAHHAL, Hassan
  • bookPart
    Ascite
    (2020) BRANDãO NETO, Rodrigo Antonio; RAHHAL, Hassan; VALENTE, Fernando Salvetti
  • bookPart
    Hiponatremia
    (2020) PINTO, Patrick Aureo Lacerda de Almeida; MARINO, Lucas Oliveira; BRANDãO NETO, Rodrigo Antonio; VALENTE, Fernando Salvetti; RAHHAL, Hassan
  • bookPart
    Comunição no departamento de emergência
    (2021) RAHHAL, Hassan; RIBEIRO, Sabrina Corrêa da Costa
  • bookPart
    Perda transitória da consciência
    (2022) BRANDãO NETO, Rodrigo Antonio; MARCHINI, Júlio Flávio Meirelles; VALENTE, Fernando Salvetti; RAHHAL, Hassan; PEREIRA, Guilherme de Abreu
  • article 39 Citação(ões) na Scopus
    Randomized trials of therapeutic heparin for COVID-19: A meta-analysis
    (2021) SHOLZBERG, Michelle; COSTA, Bruno R. da; TANG, Grace H.; RAHHAL, Hassan; ALHAMZAH, Musaad; KREUZIGER, Lisa Baumann; AINLE, Fionnuala Ni; ALMARSHOODI, Mozah Obaid; JAMES, Paula D.; LILLICRAP, David; CARRIER, Marc; BECKETT, Andrew; FRALICK, Michael; MIDDELDORP, Saskia; LEE, Agnes Y. Y.; THORPE, Kevin E.; NEGRI, Elnara Marcia; CUSHMAN, Mary; JUNI, Peter
    Background: Pulmonary endothelial injury and microcirculatory thromboses likely contribute to hypoxemic respiratory failure, the most common cause of death, in patients with COVID-19. Randomized controlled trials (RCTs) suggest differences in the effect of therapeutic heparin between moderately and severely ill patients with COVID-19. We did a systematic review and meta-analysis of RCTs to determine the effects of therapeutic heparin in hospitalized patients with COVID-19. Methods: We searched PubMed, Embase, Web of Science, medRxiv, and medical conference proceedings for RCTs comparing therapeutic heparin with usual care, excluding trials that used oral anticoagulation or intermediate doses of heparin in the experimental arm, Mantel-Haenszel fixed-effect meta-analysis was used to combine odds ratios (ORs). Results and Conclusions: There were 3 RCTs that compared therapeutic heparin to lower doses of heparin in 2854 moderately ill ward patients, and 3 RCTs in 1191 severely ill patients receiving critical care. In moderately ill patients, there was a nonsignificant reduction in all-cause death (OR, 0.76; 95% CI, 0.57-1.02), but significant reductions in the composite of death or invasive mechanical ventilation (OR, 0.77; 95% CI, 0.60 0.98), and death or any thrombotic event (OR, 0.58; 95% CI, 0.45-0.77). Organ support-free days alive (OR, 1.29; 95% CI, 1.07-1.57) were significantly increased with therapeutic heparin. There was a nonsignificant increase in major bleeding. In severely ill patients, there was no evidence for benefit of therapeutic heparin, with significant treatment-by-subgroup interactions with illness severity for all-cause death (P = .034). In conclusion, therapeutic heparin is beneficial in moderately ill patients but not in severely ill patients hospitalized with COVID-19.